The newest cathinone derivatives as designer drugs : an analytical and toxicological review by Majchrzak, Milena et al.
  
 
 
 
 
 
 
 
 
 
 
 
Title: The newest cathinone derivatives as designer drugs : an analytical and 
toxicological review 
 
Author: Milena Majchrzak, Rafał Celiński, Piotr Kuś, Teresa Kowalska, 
Mieczysław Sajewicz 
 
Citation style: Majchrzak Milena, Celiński Rafał, Kuś Piotr, Kowalska 
Teresa, Sajewicz Mieczysław. (2017). The newest cathinone derivatives as 
designer drugs : an analytical and toxicological review. "Forensic Toxicology" 
(Vol. 36, iss. 1 (2017), s. 33-50), doi 10.1007/s11419-017-0385-6 
REVIEW ARTICLE
The newest cathinone derivatives as designer drugs: an analytical
and toxicological review
Milena Majchrzak1,3 • Rafał Celin´ski3 • Piotr Kus´2 • Teresa Kowalska1 •
Mieczysław Sajewicz1
Received: 30 July 2017 / Accepted: 22 August 2017 / Published online: 7 September 2017
 The Author(s) 2017. This article is an open access publication
Abstract
Purpose Currently, among new psychoactive substances,
cathinone derivatives constitute the biggest group, which
are mainly classified into N-alkylated, 3,4-methylenedioxy-
N-alkylated, N-pyrrolidinyl, and 3,4-methylenedioxy-N-
pyrrolidinyl derivatives. These derivatives are actively
being subjected to minor modifications at the alkyl chains
or the aromatic ring to create new synthetic cathinones with
the goal of circumventing laws. In this review, the new
synthetic cathinones that have appeared on the illegal drug
market during the period 2014–2017 are highlighted, and
their characterization by gas chromatography–mass spec-
trometry and liquid chromatography–tandem mass spec-
trometry is presented.
Methods Various key words were used to conduct an
extensive literature search across a number of databases,
specifically for synthetic cathinones that emerged between
2014 and 2017.
Results More than 30 new cathinone derivatives were
discovered. The preexisting parental compounds for the
new derivatives are also referenced, and their mass spectral
data are compiled in a table to facilitate their identification
by forensic toxicologists.
Conclusions To our knowledge, this is the most current
review presenting new synthetic cathinones. Political
authorities should take measures to implement and enforce
generic scheduling (comprehensive system) laws to control
the diversely modified synthetic cathinones. Supplement-
ing the existing databases with new findings can greatly
facilitate the efforts of forensic toxicologists.
Keywords New synthetic cathinones  Designer drugs 
NPS  LC–MS  GC–MS  NMR
Introduction
Cathinone is one of the biologically active alkaloids found
in the khat shrub (Catha edulis). Due to its psychoactive
properties, khat has been known and utilized for ages by
the inhabitants of East Africa and the northeastern parts of
Arabian Peninsula. In many regions, chewing of freshly
collected khat leaves (thus liberating cathinone, which
affects the central nervous system) is considered a matter
of culture and local tradition [1–4]. Because of their
structural similarity to amphetamine, cathinone and its
analogs are often denoted as ‘‘natural amphetamines’’, and
the only structural difference between amphetamine and
cathinone is the presence of a carbonyl group in the a-
position of cathinone’s side chain. Similar to amphetamine,
cathinone and its analogs are characterized by stimulating,
euphoric, and empathogenic properties [1, 2, 4–6].
Due to their effects on the central nervous system, the
first synthetic cathinone derivatives were synthesized for
medicinal purposes in the early twentieth century, but
they began attracting wider attention around the year
2000. At that time, synthetic cathinones were included in
a broader group of psychoactive compounds denoted as
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‘‘legal drugs’’ or ‘‘designer drugs’’ [5–8]. Over the course
of the past 15 years, cathinone derivatives have gradually
become available from so-called smart shops, through the
Internet, and from drug paraphernalia stores advertising,
for example, ‘‘funny items’’ or ‘‘aromas’’ [9–11]. Syn-
thetic cathinones are most often sold as white or colored
crystalline powders, and rather rarely as tablets or cap-
sules. In the past, products containing active ingredients
from the cathinone group were advertised as ‘‘plant
nutrients’’, ‘‘bath salts’’, or ‘‘research chemicals’’. Nowa-
days, the same substances are frequently labeled with
such names as ‘‘conquerors of leeches’’, ‘‘driver’s
charms’’, ‘‘additives to sand’’, and ‘‘bidet refreshers’’.
Quite often, these preparations contain a combination of
two or more cathinone derivatives, along with other
type(s) of new psychoactive substances, caffeine, lido-
caine, or benzocaine [12].
Background
Synthetic cathinones first made their appearance in the
third decade of the twentieth century, solely for medicinal
purposes (to treat patients with parkinsonism, obesity, or
depression), but at the beginning of the twenty-first cen-
tury, they began to be consumed recreationally as sub-
stitutes for controlled drugs. After the year 2000, two
pioneering representatives from this group emerged on the
illegal market, namely CAT (methcathinone) and 4-MMC
(mephedrone, 4-methylmethcathinone), which were fol-
lowed by methylone (3,4-methylenedioxy-N-methylcathi-
none) and MDPV (3,4-methylenedioxypyrovalerone’’)
[6, 12, 13]. Immediately after their disclosure, the full
chemical and psychoactive characteristics of these com-
pounds were realized; as a consequence, in many coun-
tries, they became illegal, and clandestine synthetic
chemists began modifying their structures to obtain new
analogs. In that way, new cathinones were synthesized as
substitute drugs, including butylone, ethylone, buphe-
drone, and an analog of the latter, pentedrone, which was
soon replaced by its constitutional isomer, 4-MEC (4-
methyl-N-ethylcathinone). About the same time, the
chemical structure of mephedrone was modified by
introducing new substituents to the aromatic ring; in
2009, 4-FMC (flephedrone, 4-fluoromethcathinone) and
its positional isomer 3-FMC (3-fluoromethcathinone)
appeared. Along with pentedrone, a second-generation
synthetic cathinone, a-PVP (a-pyrrolidinopentiophenone),
appeared, which belongs to the same group [5, 6, 12].
Chemistry
The structures of the first synthetic cathinones have been
continuously modified to this day, so that each year several
new derivatives emerge on an illegal designer drug market.
Given these circumstances, the identification of these
compounds and implementation of a drug library with new
structures and their physicochemical and pharmacological
characteristics become an analytical challenge equally
important for chemists and toxicologists.
The structures of all synthetic cathinones are derived
from that of natural cathinone, and they can be considered
to be phenylalkylamine derivatives, which structurally
resemble the molecule of amphetamine with a carbonyl
group in the a-position of the side chain adjacent to the
aromatic ring. Nowadays, cathinone derivatives can be
divided into four groups. Group 1 includes N-alkyl com-
pounds or those with an alkyl or halogen substituent at any
possible position of the aromatic ring (Table 1). The
majority of the first synthetic cathinones fall into this
group, and they include ethcathinone, ephedrone, mephe-
drone, flephedrone, buphedrone, and pentedrone. Group 2
includes methylenedioxy-substituted compounds with
substituents at any given position of aromatic ring, such as
methylone, pentylone, and butylone. In terms of their
structure and pharmacological effect, these compounds are
quite similar to 3,4-methylenedioxymethamphetamine
(MDMA) (Table 2). Cathinones from group 3 (examples
given in Table 3) are analogs of natural cathinone with an
N-pyrrolidinyl substituent, and these compounds are cur-
rently the most frequently encountered in the designer drug
market. Compounds which include both methylenedioxyl
and N-pyrrolidinyl substituents belong to group 4 synthetic
cathinones (Table 4) [6].
Mechanisms of action and metabolism
In vitro experiments have shown that synthetic cathinones
easily penetrate the blood-brain barrier (BBB) [13].
Cathinone and its derivatives (denoted as b-keto-am-
phetamines) exert a stimulating and sympathomimetic
effects on the central nervous system due to an increased
concentrations of catecholamines in the inter-synapse
spaces, and their effects are generally much stronger than
that of amphetamine itself [2, 14–21]. Similar to amphe-
tamine, cathinones exist as two stereoisomeric forms, and
each is characterized by different potency [6]. The mech-
anism of action of synthetic cathinones involves the inhi-
bition of monoamine transporters such as dopamine
transporter (DAT), noradrenaline transporter (NAT), and
serotonin transporter (SERT). Depending on the derivative,
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and more precisely, on its chemical structure, their affinity
to the aforementioned transporters can be different. Dif-
ferential selectivity toward individual monoamines differ-
entiates the synthetic cathinones in terms of their effects on
neurotransmission [14, 17, 21]. Considering two properties
of synthetic cathinones, i.e., the potency of their inhibition
of dopamine, noradrenaline and serotonin reuptake as well
as their ability to liberate these compounds, Simmler et al.
[13] classified them into three groups on the basis of
in vitro experiments. The first group includes cathinones
that act in a way similar to cocaine and MDMA, and it is
denoted as the ‘‘cocaine-MDMA-mixed cathinone’’ group.
The mechanism of action of the cathinones belonging to
this group involves rather non-selective inhibition of
monoamine reuptake (in that way resembling cocaine,
which shows greater selectivity toward the dopamine
transporter than the serotonin transporter) and promotion of
serotonin liberation (similar to MDMA). Substances
Table 1 Chemical names, common names, chemical structures, and molecular weights of N-alkylated cathinone derivatives (group 1)
Chemical name Common name Chemical structure Molecular
weight [Da]
[2-(N-Methylamino)-butan-1-onyl]-
benzene
Buphedrone, a-methylaminobutyrophenone 177.24
[2-(N-Ethylamino)-propan-1- onyl]-
benzene
Ethcathinone, ETCAT, N-ethylcathinone 177.24
[2-(N-Methylamino)-propan-1-onyl]-
benzene
Ephedrone, methcathinone, CAT, a-
methylaminopropiophenone
163.22
1-[2-(N-Methylamino)-propan-1- onyl]-4-
fluorobenzene
Flephedrone, 4-FMC, 4-fluoromethcathinone 181.22
1-[2-(N-Methylamino)-propan-1- onyl]-4-
methylbenzene
Mephedrone, 4-MMC,
4-methylmethcathinone
177.24
[2-(N-Methylamino)-pentan-1- onyl]-
benzene
Pentedrone, a-methylaminovalerophenone 191.27
1-[2-(N-Methylamino)-propan-1- onyl]-
3,4-dimethylbenzene
3,4-DMMC, 3,4-dimethylmethcathinone 191.27
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belonging to this group which exhibit action similar to
cocaine include mephedrone, methylone, ethylone, and
butylone, whereas naphyrone acts similarly to MDMA
[13, 14, 16–18, 20]. The second group includes cathinones
that act similarly to methamphetamine, and its represen-
tatives are denoted as ‘‘methamphetamine-like cathi-
nones’’. Their mechanism of action involves preferential
reuptake inhibition of catecholamines and liberation of
Table 2 Chemical names, common names, chemical structures, and molecular weights of 3,4-methylenedioxy-N-alkylated cathinone deriva-
tives (group 2)
Chemical name Common name Chemical structure Molecular
weight [Da]
1-[2-(N-Methylamino)-butan-1-onyl]-(3,4-
methylenedioxy)-benzene
Butylone, bk-MBDB, b-keto-
methylbenzodioxolylbutanamine
221.25
1-[2-(N-Ethylamino)-propan-1-onyl]-(3,4-
methylenedioxy)-benzene
Ethylone, bk-MDEA, 3,4-methylenedioxy-
N-ethylcathinone
221.25
1-[2-(N-Methylamino)-propan-1-onyl]-(3,4-
methylenedioxy)-benzene
Methylone, bk-MDMA, 3,4-
methylenedioxy-N-methylcathinone
207.23
1-[2-(N-Methylamino)-pentan-1-onyl]-(3,4-
methylenedioxy)-benzene
Pentylone, bk-MBDP 235.28
Table 3 Chemical names, common names, chemical structures, and molecular weights of N-pyrrolidine cathinone derivatives (group 3)
Chemical name Common name Chemical structure Molecular weight
[Da]
1-[2-(Pyrrolidin-1-yl)-hexan-1-onyl]-4-
methylbenzene
MPHP, 4-methyl-a-
pyrrolidinohexanophenone
259.39
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-
benzene
a-PVP, a-pyrrolidinovalerophenone 231.33
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-4-
methylbenzene
Pyrovalerone, 4-methyl-a-
pyrrolidinovalerophenone
245.36
36 Forensic Toxicol (2018) 36:33–50
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dopamine, and the representatives of this group are meth-
cathinone, flephedrone, and clephedrone (4-chlorometh-
cathinone) [13, 14]. The third pharmacological effect on
neurotransmission is induced by synthetic cathinones with
structures based on that of pyrovalerone, and these com-
pounds are therefore denoted as ‘‘pyrovalerone-cathi-
nones’’. The representatives of the third group are MDPV
and MDPBP, recognized as very potent and selective
inhibitors of the catecholamine reuptake, which do not
demonstrate the neurotransmitter liberating effect [13, 15].
A cathinone classification scheme based on their interac-
tion with cathecholamines is given in Fig. 1.
Reaction symptoms of human organisms following an
intake of the discussed cathinone derivatives conform to
the aforementioned mechanism of action for the individual
cathinone groups, as revealed in the in vitro experiments
and defined on the basis of neurotransmission level [17].
The extent and strength of cathinone action on the central
nervous system can be very broad, and they depend on such
factors, as age, sex, degree of addiction, general health
condition, use of medication, an intake of other hallu-
cinogenic or psychotropic agents, and use of alcohol.
However, the subjective feelings of cathinone users are
rather similar and are said to involve strong excitation,
euphoria, increased empathy, increased self-assurance and
interpersonal openness, and increased libido [2, 5, 6, 12]. It
must be clearly stated that both chronic exposure to the
action of synthetic cathinones and a single or sporadic
intake can be equally hazardous to human health and life.
Among discomforts experienced by the consumers of ‘‘bath
salts’’ and similar products, vomiting, sweating, short-term
memory problems, migraines, feeling giddy, excessive
heart rate, and muscle tremors are most common.
Neurologically, cathinone overdose can result in memory
disturbances, memory loss, fits of panic and aggression,
hallucinations, depression, and even fits of psychoses with
suicidal thoughts [13]. From the standpoint of cardiology,
synthetic cathinones evoke elevated blood pressure, heart
arrhythmia, tachycardia, and cardiac arrest. Among the
more frequent effects of cathinone use are hyponatremia,
hyperthermia, anemia, and rhabdomyolysis [16].
The metabolism of synthetic cathinones is relatively
well known. The metabolism of mephedrone presented by
Meyer et al. [18] is understood to involve N-demethylation
to basic amines as the main mode of decomposition, fol-
lowed by reduction of the ketone functionality to
4-methylnorephedrine and hydroxylation of the methyl
substituent of the aromatic ring, which gives rise to its final
oxidation to the respective carboxylic acid. Uralets et al.
[22] studied the metabolites of 16 synthetic cathinones
found in human urine upon dividing them into three groups
of cathinone derivatives. The first group included mephe-
drone, buphedrone, 4-methylbuphedrone, pentedrone,
4-methylethcathinone (4-MEC), 3,4-DMMC, N-ethyl-
buphedrone, flephedrone, and ethcathinone, which were
metabolized following the pattern of the synthetic cathi-
none precursors (i.e., methcathinone and cathinone). In the
urine of people treated with these compounds, metabolites
resulting from b-ketone reduction and N-dealkylation were
detected—norephedrines and ephedrines as the main
metabolites. The second group included 3,4-methylene-
dioxy-substituted cathinones (i.e., methylone, butylone,
and ethylone), which exhibited less effective b-keto
reduction than the compounds from the first group, which
might be due to the presence of the 3,4-methylenedioxyl
substituent in the aromatic ring. Thus in the urine analyzed,
Table 4 Chemical names, common names, chemical structures, and molecular weights of 3,4-methylenedioxy-N-pyrrolidine cathinone
derivatives (group 4)
Chemical name Common name Chemical structure Molecular
weight [Da]
1-[2-(Pyrrolidin-1-yl)-butan-1-onyl]-3,4-
methylenedioxybenzene
MDPBP, 3,4-methylenedioxy-a-
pyrrolidinobutiophenone
261.32
1-[2-(Pyrrolidin-1-yl)-propan-1-onyl]-3,4-
methylenedioxybenzene
MDPPP, 3,4-methylenedioxy-a-
pyrrolidinopropiophenone
247.29
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-3,4-
methylenedioxybenzene
MDPV, 3,4-methylenedioxypyrovalerone 275.34
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the parent molecules were detected. The third group
included a-pyrrolidinophenones such as a-PVP and a-PBP,
which were thought not further metabolized following
reduction of the ketone group, or were found to be struc-
turally unchanged in the urine [18, 22, 23]. However,
Shima et al. [24] showed that the main metabolic pathways
of a-pyrrolidinophenones change significantly depending
on the alkyl chain length of the parent molecule in humans.
The metabolism of PV9 differed remarkably from that of
a-PVP and a-PBP. The metabolic pathways of PV9
involved reduction of the ketone group to the correspond-
ing alcohol, oxidation of the pyrrolidine ring to the corre-
sponding pyrrolidone, aliphatic oxidation of the terminal
carbon atom to the corresponding carboxylate, and
hydroxylation at the penultimate carbon atom to the
corresponding alcohol, followed by further oxidation to the
ketone, and combinations of these steps [24].
Case reports on intoxication with cathinones
The first reported death from mephedrone, one of the
earliest available and most popular designer drugs on the
market, occurred in 2008 in Sweden [25]. Since then, 45
mephedrone-induced deaths have been reported in Eng-
land, 12 fatal cases in Scotland, one each in Wales and
North Ireland, and one in Guernsey Island [26]. By August
2011, 90 documented cases of death related to mephedrone
intoxication had been reported in Great Britain. The
majority of the victims were young males between 25 and
34 years of age, with documented past histories of drug
abuse [26]. In 2013, Adamowicz et al. [27] described a case
of fatal intoxication caused by mephedrone in Poland. The
first documented case of fatal overdose with MDPV
occurred in the USA in 2012, and was followed by two
similar deaths (20-year-old male and 48-year-old female)
[28]. Methylone and MDPV (together with mephedrone)
have caused the death of several individuals between the
age of 19–38 during a similar time period [29]. An
expanding library of synthetic cathinones has resulted in
the intake of new brand compounds, with potencies that are
unprecedented, even among drug users. Quite often, drug
consumers are not even aware of which psychoactive
compounds are present in the product that they are going to
take [30]. Most recently, the first death caused by the
newest generation of synthetic cathinones available on the
synthetic drug market was reported by Hasegawa et al.
[31]; they described a case of PV9 intoxication involving
an 18-year-old female who developed convulsions and
muscle trembling, and who finally lost consciousness upon
intake of an ‘‘aroma liquid’’. Despite nearly 20 h of intense
medical rescue efforts (which consisted of gastric lavage
and intravenous transfusions), the girl eventually died.
Nine tissues were collected from her body in the course of
autopsy, i.e., skeletal muscle, pancreas, fat tissue, kidney,
liver, lung, spleen, heart muscle, and brain. The highest
concentration of PV9 (1-phenyl-2-(pyrrolidin-1-yl)octan-1-
one) was detected in the kidney, which suggested fast
removal of this compound via the urine. The first multiple
drug intoxication caused by the simultaneous ingestion of
three cathinone derivatives (i.e., 4-methoxy-PV8, PV9, and
4-methoxy-PV9) was reported by Kudo et al. [32]; a
woman in her 30s was found dead after consuming alcohol,
and the ‘‘aroma drugs’’ and ‘‘bath salts’’ were found next to
her body.
Fig. 1 Chemical structures of a cocaine-MDMA-mixed cathinones,
b methamphetamine-like cathinones, and c pyrovalerone-cathinones
as a function of their in vitro pharmacological activities
38 Forensic Toxicol (2018) 36:33–50
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Extraction methods
From an analytical point of view, the proper preparation of
samples for instrumental analysis is a crucial and decisive
step. This section deals with the analysis of biological
material (blood, urine, or body tissues), which is usually a
challenging task due to the possible presence of a vast
number of metabolites and other biochemical components
of the samples, which can jointly generate considerable
measurement errors. Only the adequate extraction of a
biological matrix allows an accurate quantification of toxic
compounds while preventing the contamination of sensi-
tive analytical instruments with impurities. The most fre-
quently applied techniques for the isolation of psychoactive
and hallucinogenic compounds from biological matrices
are liquid-liquid extraction (LLE) and solid-phase extrac-
tion (SPE). Detailed working parameters for these tech-
niques depend on the type of tissue analyzed and on the
chemical nature of the substance of interest (mainly, on its
acidity or basicity). In the paper by Dickson et al. [33], the
following method for preparation of the autopsy material
was described for basic drug screening: to 1 or 2 mL liquid
sample, ca. 3 mL 0.1 M phosphate buffer (pH 6) and an
internal standard (mepivacaine or ethylmorphine at the
concentration of 0.5 mg L-1) were added, and then the
thus prepared mixture was ultrasonicated for 15 min and
centrifuged. The prepared samples were applied to the top
of the SPE cartridges (mixed-mode silica-based SPE,
ZCDAU020) which were previously conditioned with
3 mL methanol, 3 mL deionized water, and 2 mL of the
same phosphate buffer. After that, the cartridges were
rinsed with 2 mL deionized water, 2 mL 20% aqueous
acetonitrile, and 2 mL 0.1 M acetic acid. Finally, the car-
tridges were dried for 3 min in vacuum, ultimately rinsed
with 2 mL hexane and 3 mL methanol, and once again
dried for 10 min in vacuum. The adsorbed analytes were
then eluted with 3 mL dichloromethane/isopropanol/am-
monium hydroxide (78:20:2, v/v/v), and after evaporation
of solvent under a stream of nitrogen and dissolution of the
residue in 50 lL acetonitrile, the samples were ready for
instrumental analysis. The analogous SPE procedures were
applied by other toxicological analysts during their inves-
tigations of intoxications involving cathinone derivatives
[34, 35].The innovative introduction of the QuEChERS
technique for toxicological analysis should be mentioned in
most up-to-the-date reports on the identification of syn-
thetic cathinones from postmortem samples. This quick
(Qu), easy (E), cheap (Ch), effective (E), rugged (R) and
safe (S) approach was initially introduced for the quan-
tification of pesticide contaminants in food. Application of
this approach to toxicological analysis was motivated by
the fact that the LLE and SPE approaches are subject to the
possible contamination of samples by unwanted impurities
that give rise to inaccurate final results and negative matrix
effects on sensitive analytical instruments. Thus, in 2012,
Usui et al. [36] applied the QuEChERS method for rapid
extraction of psychoactive substances from human blood,
which demonstrated selectivity comparable to SPE, and
was as simple as LLE. QuEChERS was also much faster
and cheaper than both LLE and SPE. This was a two-step
procedure. In the first step (denoted as extraction/parti-
tioning), liquid samples (e.g., blood) undergo triple dilution
with distilled water, and then they are placed in plastic test
tubes that contain 0.5 g of a commercial preparation
composed of magnesium sulfate and sodium acetate, a
stainless steel bead, and 1 mL acetonitrile containing IS.
The contents of the test tube are intensely mixed and
centrifuged. With acidic analytes, the obtained acetonitrile
layer can be subjected directly to instrumental analysis. To
extract basic compounds, the second step must also be
performed, i.e., the ‘‘dispersive solid phase extraction
(dSPE)’’, which involves introducing 600 lL acetonitrile
supernatant to a test tube containing a commercial mixture
of N-propylethylenediamine (primary secondary amine,
PSA), a portion of an end-capped octadecylsilane, and
magnesium sulfate, for purification. Then the test tube
contents are mixed and centrifuged, and an upper layer is
subjected to instrumental analysis. Because of the advan-
tages of the this method (i.e., its speed, lower risk of the
instrument contamination, and general cost-effectiveness),
it is now the most frequently used analytical approach
(either directly or with minor modifications to the proce-
dure) for toxicological analysis of biological samples
[36, 37].
Detection techniques
The steadily growing market of designer drugs poses a
permanent analytical challenge for those who focus on the
physicochemical characterization of drugs and their iden-
tification in biological samples. Apart from the key stage of
sample preparation, a crucial role is played by analytical
techniques used to assess the chemical composition of
these drugs. Considerable progress in chromatographic and
spectroscopic techniques (resulting in sophisticated
instruments able to identify hundreds of compounds in
nanomole concentrations) allows the scope of toxicological
investigations to be expanded from the currently sear-
ched—both known and unknown—designer drug mole-
cules to their metabolites [38, 39]. Each of these two
analytical techniques has praiseworthy advantages, and
both carry certain drawbacks at the same time; however,
the combination of the two methods provides a powerful
Forensic Toxicol (2018) 36:33–50 39
123
tool for the identification and quantification of cathinones
in products and in biological samples [38–43].
Practically all attempts to identify psychoactive com-
pounds (the cathinone derivatives included) begin with the
application of the non-specific screening methods. In the
case of product samples (e.g., powders, tablets and the
contents of capsules), standard colorimetric methods are
used, and they constitute a routine service in most analyt-
ical institutions, including police forensic laboratories
[43, 44]. The most common test for compounds which
contain a nitrogen atom (widely used for identification of
amphetamine) makes use of the Marquis reagent (sulfuric
acid and formaldehyde). It does not give rise to a color
reaction with synthetic cathinones derived from mephe-
drone, but it gives positive results with the compounds
containing the methylenedioxyl substituent, such as
MDPV. For this latter cathinone, an additional test with the
Chen reagent (acetic acid, copper monosulfide, and sodium
hydroxide) can also be applied, and this test is suitable for
the ephedrine derivatives as well [44]. Colorimetric tech-
niques are advantageous in the sense that they are rapid and
easy to apply. However, they usually only allow identifi-
cation of a single structural fragment of a given molecule,
which is not a sufficient criterion for designating a com-
pound to a given group of derivatives. Because of this
shortcoming, the identification of synthetic cathinones
cannot be carried out via the use of colorimetric methods;
they are generally not used for the preliminary screening of
designer drugs.
The screening of biological material is most often car-
ried out through the use of immunoenzymatic assays. The
most common assay is ELISA (enzyme-linked
immunosorbent assay), which is devised to detect certain
psychoactive substances in an investigated sample via
mono- or polyclonal antibodies coupled with an enzyme.
This technique is very popular in biomedical analysis, e.g.,
in virology (the HIV test) and bacteriology (the
mycobacterium test) and in food analysis targeting poten-
tial allergens [45]. In most commercial laboratories,
immunoenzymatic assays for toxicological purposes are
also applied. It can be used as a screening technique for the
detection of synthetic cathinones in biological samples
[46, 47], but it is considered to be non-specific due to
possible cross reactions, such as the reaction between
MDPV and butylone [47].
Screening analyses can be used as a preliminary step in
an assessment of product samples and/or biological sam-
ples for the presence of psychoactive compounds. Their
results often indicate a point of focus for further investi-
gations with a narrower group of suspected compounds, but
a decisive role is played by specific analytical techniques.
For synthetic cathinones, the analytical techniques of first
choice are gas chromatography (GC) and liquid chro-
matography (LC) coupled with different spectroscopic
instruments.
Gas chromatography–mass spectrometry (GC–MS) is
the most frequently used instrumental technique for toxi-
cological analysis. It is applicable to many volatile psy-
choactive compounds (cathinones included)
[35, 37, 43, 48–52]. Moreover, the time of a single ana-
lytical run is relatively short and within the period of ca.
40 min; a vast number of compounds can be screened in
this way [48]. During GC–MS, chemical ionization (CI) is
occasionally applied [48], but in most cases, the electron-
ionization (EI) mode predominates [35, 37, 43, 48–52].
The cathinone mass spectrum originating from GC–MS in
the positive ionization mode is very simple and charac-
terized by signals derived from the iminium ions. However,
identification of different cathinone derivatives becomes
rather complicated [35, 48–52]. For this reason, different
modifications of the detection are highly valuable. Tandem
mass spectrometry (MS/MS) constitutes one such method
which provides more information about the molecular
structure and greatly facilitates identification. In 2012,
Zuba [48] proposed a novel analytical procedure for the
determination of synthetic cathinones by means of GC–EI-
MS. According to his approach, if the iminium ion appears
as an intense ion (m/z = 16 ? 14n, where n = 1, 2, 3 etc.),
it can be assumed that the cathinone present in the analyzed
sample is characterized by having a straight aliphatic chain.
If in the mass spectrum a signal appears which corresponds
to the pyrrolidine ion (m/z = 70 ? 14n, where n = 1, 2, 3
etc.), then the identified cathinone should contain a
pyrrolidine ring. Due to the possible existence of many
different regioisomers for different cathinone derivatives,
the assessment of the aliphatic chain length and its possible
substituents and identification of the substituents on the
aromatic ring define essential tasks. With unsubstituted
rings, the presence of the fragmentation ions at m/z 77 and/
or 105 is characteristic. Signals at m/z 91 and/or 119 are
characteristic of the methylphenyl ring, and those at m/z
121 and/or 149 suggest the presence of the methylene-
dioxyl ring substituent. The GC–EI-MS technique is rapid,
yet its main drawbacks include the possible emergence of
identical fragmentation patterns for certain isomers and the
low intensity of molecular ions when applying the EI
mode. These are the main reasons why the application of
alternative mass spectrometric techniques often becomes
inevitable [48].
However, recently, the effective use of GC–EI-MS/MS
for distinguishing certain regioisomers of cathinone
derivatives has been reported in the literature [49]. An
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effective method for fragmentation of iminium ions has
been described, which makes it possible to clearly distin-
guish cathinone derivatives with the same aminoalkyl
moiety. For example, in the case of pentedrone, N-ethyl-
buphedrone, 4-methyl-N-dimethylbuphedrone, and N-
ethylmethcathinone, it has been shown that secondary and
tertiary fragmentation of the iminium ion is useful for the
differentiation of the above four compounds; the com-
pounds can be discriminated by GC–MS/MS based on the
intensity difference of the product ions originating from the
iminium ion. This work has proposed that various cathi-
nones and forthcoming novel illicit drugs can be differen-
tiated based on a detailed analysis of product ion spectra
derived from the iminium and acylium ions, if combined
with an LC-photodiode array (PDA) analysis [49].
Liquid chromatography–mass spectrometry (LC–MS) is
employed in toxicological analysis laboratories nearly as
frequently as GC–MS, and enjoys high popularity due to its
high sensitivity and selectivity [38, 39, 53]. Most LC–MS
analyses are carried out in the tandem MS mode with the
multiple reaction monitoring (MRM) or the selected reac-
tion monitoring (SRM) mode, and the most frequently used
ionization interface is electrospray ionization (ESI)
[52–54]. In the case of synthetic cathinones, a vast number
of analyses have been carried out in the ESI-MSn mode,
which has enabled observation of product ion formation
patterns characteristic of the respective protonated molec-
ular ions. Characteristic features of the product ion for-
mation include the loss of a water molecule and the split-
off of the pyrrolidine ring [53]. Lesiak et al. [42] presented
a different type of analysis in the context of a mixture of
cathinone derivatives present in a commercial product
labeled as a ‘‘bath salt’’. These authors admitted that the
most popular and most frequently applied analytical tech-
niques were GC–MS and LC–MS supported by libraries of
mass spectra, but the utility of these approaches is
declining in the face of the avalanche of novel cathinone
derivatives that appear with increasing frequency on the
designer drug market. As an alternative, these authors
proposed application of the DART (direct analysis in real
time) ionization source coupled with the mass spectrome-
ter. The results obtained with this approach pointed to its
greater utility and enhanced capacity to differentiate
compounds that are structurally closely related or even
isomeric, both as individual species and as the components
of mixtures. Ultra-high-performance liquid chromatogra-
phy (UHPLC) coupled with time-of-flight mass spectrom-
etry (TOF-MS) and its quadrupole TOF (QTOF)
modification is an additional technique which can be used
for analysis of the active ingredients in designer drugs.
Using these latter techniques, Iba´n˜ez et al. [41] success-
fully identified compounds (including certain cathinone
derivatives) present in numerous designer drugs
commercialized as tablets, capsules, powders, and dried
herbs. The results obtained by these authors demonstrated
the high potential of the discussed techniques in applica-
tions toward both ‘‘target analysis’’ and ‘‘non-target anal-
ysis’’ of psychoactive compounds, where each newly
emerging compound was regarded as an unknown sub-
stance. An advantage of the QTOF-MS-based methods is
that preliminary identification of the analyzed compounds
can be performed without any reference standards; at the
initial stage of investigations they are not needed. Refer-
ence standards are only acquired at the final stage of
investigations to ultimately confirm the presence of a given
compound, once solid instrumental evidence is already at
hand.
A less frequently employed detection system, also
applied during the investigation of drug products and bio-
logical samples, is LC coupled with ultraviolet-visible
(UV-Vis) spectroscopy using diode array or PDA detection
[53, 55–58]. With this detection system, one can record the
UV-Vis spectra of the investigated cathinones and establish
the absorption wavelength characteristics of the individual
group representatives. These data can be added to a library,
thus providing physicochemical characteristics of individ-
ual cathinone species.
Last but not least, in the context of the structural elu-
cidation of cathinone derivatives, during the analysis of the
evidence material, the nuclear magnetic resonance (NMR)
and infrared absorption spectroscopy cannot be forgotten
[40, 52, 53]. By way of NMR spectroscopy, the substitu-
tional isomerism of a given molecule can be defined
without using a reference standard. Obviously, this tech-
nique cannot be employed to quantify the contents of
psychoactive substances in biological material, but 1H and
13C NMR spectroscopy are commonly used for detailed
assessment of the chemical structures of cathinone
derivatives, including their substitutional isomerism
[40, 52, 53, 59].
Most recently described derivatives and their
characterization
Due to the wide-ranging possibility for structural modifi-
cation of cathinones, new compounds from this group are
continuously emerging on the global designer drug market,
and thus their identification and physicochemical charac-
terization pose a serious analytical challenge. The
exchange of information on new derivatives, including the
full physicochemical characteristics of these compounds,
and proposals for methods that are uniquely suited for their
identification, combined with reports on cases of intoxi-
cation, contribute to the dynamically developing field of
toxicological analysis.
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Table 5 Chemical names, common names, and chemical structures of the most recently reported cathinone derivatives, along with respective
reference sources, arranged according to the featured structures
Chemical name Common name Chemical structure Publication year
and reference
2-Methylamino-1-(phenyl)hexan-1-one Hexedrone, HEX 2017 [62]
1-(4-Chlorophenyl)-2-(methylamino)-
pentan-1-one
4-Cl-pentedrone 2017 [61]
1-(4-Methylphenyl)-2-(methylamino)-
pentanone
4-Methylpentedrone, 4-MPD 2017 [63]
1-[2-(N-Ethylamino)-pentan-1- onyl]-
benzene
a-EAPP, a-ethylaminopentiophenone 2014 [55]
2-(Ethylamino)-1-phenylhexan-1-one N-Ethylhexedrone 2017 [61]
1-(4-Chlorophenyl)-2-
(ethylamino)pentan-1-one
4-Cl-EAPP 2017 [61]
1-(4-Bromophenyl)-2-
(ethylamino)propan-1-one
4-Bromoethcathinone, 4-BEC 2017 [62]
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Table 5 continued
Chemical name Common name Chemical structure Publication year
and reference
1-[2-(N-Ethylamino)-pentan-1- onyl]-4-
methylbenzene
N-Ethyl-4-methylpentedrone,
4-methyl-a-
ethylaminopentiophenone
2014 [55]
1-(3,4-Methylenedioxyphenyl)-2-
ethylaminopentan-1-one
N-Ethylnorpentylone, bk-EPDP, N-
ethylpentylone
2017 [61, 63]
1-(3,4-Methylenedioxyphenyl)-2-
propylaminopropan-1-one
Propylone 2017 [61]
1-(6-Methoxy-3,4-
methylenedioxyphenyl)-2-
methylaminopropan-1-one
6-Methoxy-bk-MDMA 2017 [61]
1-[2-(Pyrrolidin-1-yl)-hexan-1- onyl]-
benzene
a-PHP, a-pyrrolidinohexanophenone 2014 [57]
4-Methyl-1-phenyl-2-(pyrrolidin-1-
yl)pentan-1-one
a-PiHP 2017 [61]
1-[2-(Pyrrolidin-1-yl)-heptan-1- onyl]-
benzene
a-PHPP, PV8, a-
pyrrolidinoheptanophenone
2014 [55]
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Table 5 continued
Chemical name Common name Chemical structure Publication year
and reference
1-[2-(Pyrrolidin-1-yl)-octan-1- onyl]-
benzene
a-POP, PV9, a-pyrrolidino-
octanophenone
2014 [55]
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-4-
fluorobenzene
4-F-a-PVP, 4-fluoro-a-
pyrrolidinopentiophenone
2014 [55]
1-(4-Fluophenyl)-2-(pyrrolidin-1-
yl)hexan-1-one
4-F-a-PHP 2017 [61]
1-[2-(Pyrrolidin-1-yl)-heptan-1- onyl]-
4-fluorobenzene
4-F-a-PHPP, 4-fluoro-a-
pyrrolidinoheptanophenone
2014 [57]
1-[2-(Pyrrolidin-1-yl)-octan-1- onyl]-4-
fluorobenzene
4-F-a-PV9, 4-fluoro-a-POP, 4-fluoro-
a-pyrrolidinooctanophenone
2016 [53]
1-(4-Chlorophenyl)-2-(pyrrolidin-1-
yl)propan-1-one
4-Cl-a-PPP 2017 [62]
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Table 5 continued
Chemical name Common name Chemical structure Publication year
and reference
1-(4-Chlorophenyl)-2-(pyrrolidin-1-
yl)hexan-1-one
4-Cl-a-PHP 2017 [61]
1-(4-Bromophenyl)-2-(pyrrolidin-1-
yl)pentan-1-one
4-Br-a-PVP 2017 [62]
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-4-
methoxybenzene
4-Methoxy-a-PVP, 4-methoxy-a-
pyrrolidinopentiophenone
2014 [56]
1-[2-(Pyrrolidin-1-yl)-heptan-1-onyl]-4-
methoxybenzene
4-Methoxy-a-PHPP, 4-methoxy-a-
pyrrolidinoheptanophenone
2014 [57]
1-[2-(Pyrrolidin-1-yl)-octan-1- onyl]-4-
methoxybenzene
4-Methoxy-a-POP, 4-methoxy-a-
pyrrolidinooctanophenone
2014 [57]
1-[2-(Pyrrolidin-1-yl)-pentan-1-onyl]-
3,4-dimethoxybenzene
3,4-Dimethoxy-a-PVP, 3,4-
dimethoxy-a-
pyrrolidinopentiophenone
2014 [55]
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Beginning in early 2000s, when synthetic cathinones
first appeared on the market [6], new derivatives have been
continuously reported in the literature [8, 9, 11]. In the past
2 years, over a dozen new cathinone derivatives have been
commercialized [9]. In mid-2013, a methoxy derivative
was identified for an already known synthetic cathinone, a-
PVP (i.e., 4-methoxy-a-PVP [56]), in a product which also
contained 4-methylbuphedrone. Then, in March of 2014,
Uchiyama et al. [55] reported as many as seven new syn-
thetic cathinones. The authors analyzed multicolored liq-
uids marketed as ‘‘aroma liquids’’ and colored powders
advertised as ‘‘fragrance powders’’. First, all of these liq-
uids and powders were subject to liquid extraction, after
which 2-mg aliquots of powders and 20-lL aliquots of
liquids were extracted with 1 mL methanol through the use
of ultrasonication. After centrifugation and filtering, if
necessary, the obtained supernatants were diluted and
subsequently analyzed by ultra-high-performance liquid
chromatograph coupled with ESI-MS and GC–EI-MS. The
exact molar mass (Da)-to-charge (z) ratios of the com-
pounds of interest (m/z) were measured by LC–QTOF-MS.
Additionally, the structures of all of these new derivatives
were confirmed by means of 1H and 13C NMR spec-
troscopy. This study resulted in the identification of seven
new cathinones, i.e., MPHP (4-methyl-a-pyrrolidinohex-
anophenone), a-PHPP (a-pyrrolidinoheptanophenone,
PV8), a-POP (a-pyrrolidinooctanophenone, PV9), 3,4-
dimethoxy-a-PVP (3,4-dimethoxy-a-pyrrolidinopentio-
phenone), 4-F-a-PVP (4-fluoro-a-pyrrolidinopentiophe-
none), a-EAPP (a-ethylaminopentiophenone), and N-ethyl-
4-methylpentedrone (4-methyl-a-ethylaminopentiophe-
none). Less than a half year later, and using the same
Table 5 continued
Chemical name Common name Chemical structure Publication year
and reference
2-(Methylamino)-1-(2-thienyl)-1-
propanone
Thiothinone 2016 [54]
2-(Pyrrolidin-1-yl)-1-(thiophen-2-
yl)butan-1-one
a-PBT 2016 [60]
1-(5-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)butan-1-one
5-Br-a-PBT 2016 [60]
x = Br
y = z = H
1-(4-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)butan-1-one
4-Br-a-PBT
y = Br
x = z = H
1-(3-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)butan-1-one
3-Br-a-PBT
z = Br
x = y = H
1-(5-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)pentan-1-one
5-Br-a-PVT 2016 [60]
x = Br
y = z = H
1-(4-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)pentan-1-one
4-Br-a-PVT
y = Br
x = z = H
1-(3-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)pentan-1-one
3-Br-a-PVT
z = Br
x = y = H
1-(4,5-Bromothiophen-2-yl)-2-
(pyrrolidin-1-yl)pentan-1-one
4,5-Br-a-PVT
x = y = Br
z = H
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Table 6 Common names, absorption maxima, molecular weights,
liquid chromatography–electrospray ionization-tandem mass spec-
trometry (LC–ESI-MS/MS) peaks, gas chromatography–electron
ionization-mass spectrometry (GC–EI-MS) peaks, and references
for the most recently reported cathinone derivatives, arranged
according to the featured structures
Common name Absorption
maxima
[nm]
Molecular
weight [Da]
Precursor ion [M ? H?] and product ions
by LC–ESI-MS/MS [m/z]
Base peak and other peaks of
GC–EI-MS spectrum [m/z]
Reference
Hexedrone, HEX 224 205.15 206, 188, 132, 175, 100, 105, 119, 91 100, 77, 69, 44, 58 [62]
4-Cl-pentedrone No data 225.10 226, 144, 208, 125, 166, 164, 178, 173,
131, 138
86, 44 [61]
4-Methylpentedrone,
4-MPD
– 205.15 206, 188, 158, 146, 145, 144, 131, 130 86 [63]
a-EAPP 251 205.30 206 100, 77 [55]
N-Ethylhexedrone No data 219.17 220, 130, 202, 146, 91, 158, 175 114, 105, 58 [61]
4-Cl-EAPP No data 239.12 240, 158, 164, 125, 180, 138, 187, 145,
195, 192
100, 58 [61]
4-Bromoethcathinone,
4-BEC
265 255.03 256/258, 159, 144, 132 72, 44, 185, 155 [62]
N-Ethyl-4-
methylpentedrone
264 219.32 220 100, 91 [55]
N-Ethylnorpentylone,
bk-EPDP, N-
ethylpentylone
No data 249.14 250, 202, 189, 232, 175, 203, 149, 173 100, 149, 91, 58 [61, 63]
Propylone No data 235.13 236, 188, 146, 218, 175, 160, 118 86, 149, 135, 121, 44 [61]
6-Methoxy-bk-
MDMA
No data 237.11 238, 190, 175, 58 58, 204, 179 [61]
a-PHP 252, 251 245.36 246, 228, 175 140, 141, 105, 96, 77 [53, 57]
a-PiHP No data 245.19 246, 140, 91, 119 140, 188, 98, 84 [61]
a-PHPP, PV8 253 259.39 260 154, 105, 77 [55]
a-POP, PV9 253 273.41 274 168, 105, 77 [55]
4-F-a-PVP 256 249.32 250 126, 95 [55]
4-F-a-PHP No data 263.18 264, 140, 123, 109, 190, 137 140, 123, 96, 84, 69 [61]
4-F-a-PHPP 255 277.38 278 154, 123, 95 [57]
4-F-a-PV9, 4-F-a-
POP
254, 253 291.40 292, 274, 221, 203, 189 168, 169, 123, 110, 95, 84, 55 [53]
4-Cl-a-PPP 263 237.10 238, 167, 185, 139, 98 98, 56, 111, 69 [62]
4-Cl-a-PHP No data 279.15 280, 125, 140, 138, 209 140, 111, 84 [61]
4-Br-a-PVP 267 309.08 310/312, 160, 126, 168, 131, 183 126, 183, 155, 84 [62]
4-Methoxy-a-PVP 292 261.36 262 126, 135, 107 [56]
4-Methoxy-a-PHPP 292 289.41 290 154, 135 [57]
4-Methoxy-a-POP 292 303.44 304 168, 135 [57]
3,4-Dimethoxy-a-
PVP
286, 316 291.39 292 126, 137, 165 [55]
Thiothinone No data 169.24 170 58, 83, 111 [54]
a-PBT No data 223.33 224 112 [60]
5-Br-a-PBT No data 302.23 302/304 112 [60]
4-Br-a-PBT 302/304 112
3-Br-a-PBT 302/304 112
5-Br-a-PVT No data 316.26 316/318 126, 189, 191 [60]
4-Br-a-PVT 316/318 126, 189, 191
3-Br-a-PVT 316/318 126, 189, 191
4,5-Br-a-PVT 395.15 393/395 126, 267, 269, 271
The boldface figures shown in the data for LC–ESI-MS/MS and GC–EI-MS are precursor ions and base peaks, respectively
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extraction and analytical approach, Uchiyama et al. [57]
added four newly identified compounds to the database of
synthetic cathinones, i.e., a-PHP (a-pyrrolidinohex-
anophenone), 4-methoxy-a-POP (4-methoxy-a-pyrrolidi-
nooctanophenone), 4-methoxy-a-PHPP (4-methoxy-a-
pyrrolidinoheptanophenone), and 4-F-a-PHPP (4-fluoro-a-
pyrrolidinoheptanophenone). In addition, a growing ten-
dency was noted for the delivery of mixtures of designer
drugs in commercialized products. These were usually
binary and ternary mixtures and not necessarily of a single
class of compounds, but instead consisted of drugs
belonging to different groups (e.g., as combinations of
synthetic cathinones and synthetic cannabinoids) [55–57].
Due to the unknown mechanism of action and toxicity of
these new psychoactive compounds, their combination can
result in an unexpected synergism and consequently jeop-
ardize the health and life of the potential drug takers.
In the second half of 2015, Doi et al. [60] reported for
the first time the discovery of thienyl cathinone derivatives
in commercialized designer drugs, including a-PBT (a-
pyrrolidinobutiothiophenone), and in addition, the bro-
mothienyl analogs of a-PVT (a-pyrrolidinopentiothiophe-
none) and a-PBT. At approximately the same time,
Gambaro et al. [54] reported on a new cathinone derivative,
thiothinone [(2-methylamino)-1-(2-thienyl)-1-propanone].
Complementary information and an expansion of the
physicochemical database regarding a-PHP, along with
the first report on a new cathinone derivative, 4-fluoro-
PV9 (4-fluoro-a-pyrrolidinooctanophenone), were pro-
vided by our research group at the end of 2015 [53].
Apart from standard applications of LC–MS, GC–MS,
and NMR, the authors characterized these two com-
pounds through the use of MS/MS with electrospray
ionization (ESI-MSn), Fourier transform infrared spec-
troscopy, differential scanning calorimetry, and ther-
mogravimetric analysis. Moreover, the analyzed
materials (multicolored powders) were not extracted
with methanol; instead they were treated with in-home
elaborated solvent systems. In the first stage, 10 mg of a
given powder was dissolved in 1 mL acetonitrile/
methanol (50:50, v/v), then ultrasonicated and cen-
trifuged, and the obtained supernatant was dissolved in
methanol/water (80:20, v/v) for instrumental analysis
[53].
Full characterization of nine new cathinones—N-ethyl-
hexedrone, 4-Cl-pentedrone, 4-Cl-EAPP, propylone, N-
ethylnorpentylone, 6-methoxy-bk-MDMA, a-PiHP, 4-Cl-
a-PHP, and 4-F-a-PHP—was described by Liu et al. [61].
This year, Bła _zewicz et al. [62] described four novel
synthetic cathinones—hexedrone, 4-BEC, 4-Cl-PPP, and
4-Br-PVP [62]. In May of this year, three new cathinone
derivatives—4-MPD, 4-F-a-PHP, and bk-EPDP—were
also described [63].
In Table 5, the names and structures of recently reported
cathinone derivatives are shown according to the featured
structures.
In Table 6, a summary of analytical data for the recently
reported cathinone derivatives is listed also according to
the featured structures.
Conclusions
Over the past 3 years, synthetic cathinones (along with
synthetic cannabinoids) found in commercialized products
and biological samples have been the most frequently
identified group of designer drugs. Legislative efforts
undertaken in many countries, including Poland, tend to
eliminate them from the legal drug markets by adding them
to lists of forbidden substances. However, the laboratories
which produce novel psychoactive substances do not
undergo toxicological or pharmacological control and can
thus easily circumvent the law by freely introducing new
derivatives which do not appear on the lists of forbidden
substances. From the structures of synthetic cathinones that
have been synthesized in the past 3 years and discussed in
this review, it is clear that structural modification of the
cathinone skeleton is virtually limitless. The structural
diversity of already-synthesized cathinone derivatives
encourages further modifications, mainly through the
introduction of novel alkyl, alkoxy, or halogen substituents
to the aromatic ring, and by playing with the length of the
alkyl chain at the a-carbon atom. From the casualties
reportedly caused by synthetic cathinones, it is clear that
young people are the most vulnerable population group, as
they are apt to experiment with novel designer drugs. In
view of the imaginative and dynamic progress with respect
to the synthesis of novel cathinone derivatives and the
resulting adverse health effects and mortality, the generic
scheduling of possession and/or use of substances which
include a synthetic cathinone and its structurally modified
derivatives seems to be the only legal remedy. For the time
being, the identification and physicochemical characteri-
zation of novel synthetic cathinones constantly emerging
on the designer drug market pose a considerable challenge
for analytical chemists. Supplementing the existing data-
bases with novel findings can significantly facilitate the
efforts of toxicologists.
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